University of Ottawa Heart Institute

HEAD ICU DOCTOR KWADWO KYEREMANTENG SCHEDULED TO GUEST ON CTV’S ‘THE SOCIAL’ TO SPEAK ABOUT RACISM IN HEALTHCARE

Retrieved on: 
Tuesday, January 10, 2023
CTV News, Intensive care unit, Racism, Critical care, Caregiver, CBC, Interview, Palliative care, RON, University of Ottawa Heart Institute, Social, The Ottawa Hospital, Knowledge, CityNews, CTV, Conference, ICU, News, Patient, White, Black History Month, Pediatric intensive care unit, University, Medicine, International Conference on Population and Development, Human, Dignity, Hospital, Medical device

Racism in healthcare, also known as medical racism, is systemic discriminatory and targeted practices and behaviours towards people based on their race and ethnicity in healthcare.

Key Points: 
  • Racism in healthcare, also known as medical racism, is systemic discriminatory and targeted practices and behaviours towards people based on their race and ethnicity in healthcare.
  • Medical racism has historically affected Black people in North America through biases held by caregivers, disparities in health coverage, effects from racism outside of healthcare, and more.
  • - Dr. Kwadwo Kyeremanteng in "Racism in healthcare still exists and must be called out, local doctor says" by CityNews
    “What I encourage all of us to do, especially our White community: be an ally.
  • An important aspect of creating a more efficient ICU for all, is understanding how to fight medical racism.

Major investment in top talent in ALS research

Retrieved on: 
Thursday, November 24, 2022
Municipal government in Canada, Doctor of Philosophy, Western University, Organization, ALS Society of Canada, Society, Fellow, University, Health Canada, Knowledge, Partnership, Brain, Education, Friends, Research, Fondation Botnar, Disease, Sunnybrook Research Institute, ALS, Ill, University of Ottawa Heart Institute, Amyotrophic lateral sclerosis, Medical device, Medicine, Dentistry, Hospital

Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS) through exciting new research funding.

Key Points: 
  • Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS) through exciting new research funding.
  • Being able to move the needle on ALS research means supporting the brightest minds that will be a key component of labs focused on improving the lives of people and families living with ALS, says Dr. David Taylor, Vice President Research and Strategic Partnerships, ALS Canada.
  • Through the ALS Canada Research Program, we fund peer-reviewed research grants, foster collaboration and build capacity within Canadas ALS research and clinical community, and invest in new areas of research positioned to have high impact.
  • As the only national dedicated source of funding for ALS research across Canada, the ALS Canada Research Program aims to accelerate research impact by providing funding for the most promising ALS projects focused on translating scientific discoveries into treatments for ALS.

Fifth Eye Announces Andrew Malcolmson as new President & CEO

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Vital signs, IOS, Growth, Board of directors, Clinical decision support system, General manager, Bachelor of Science in Nursing, Intelligence, Board, Industry, Risk, Malcolmson, AHI, Hemodynamics, Lead, Danaher, Judgement, Sale, Technology, Health care, Master of Science in Health Informatics, ANN, Chemical engineering, University, FDA, Patient, University of Ottawa Heart Institute, Caregiver, Medical device, Medicine, Science

ANN ARBOR, Mich., Nov. 1, 2022 /PRNewswire/ -- Fifth Eye , a leading provider of real-time AI-based clinical analytics today announced that its Board of Directors has appointed Andrew Malcolmson as its new President and Chief Executive Officer.

Key Points: 
  • ANN ARBOR, Mich., Nov. 1, 2022 /PRNewswire/ -- Fifth Eye , a leading provider of real-time AI-based clinical analytics today announced that its Board of Directors has appointed Andrew Malcolmson as its new President and Chief Executive Officer.
  • Andrew replaces Jen Baird who founded and led Fifth Eye from conception through product development, FDA clearance, and initial commercial release of their Analytic for Hemodynamic Instability (AHI) System.
  • Prior to joining Fifth Eye, Malcolmson was the General Manager of the Intra Oral Scanning (IOS) business unit at Carestream Dental where he recently led the $600M carve-out and sale of the business to Envista Holdings Corp.
    "Andrew has extensive experience in building partnerships that deliver strategic sales growth," Robert Kline, Executive Chairman, Fifth Eye, said.
  • Andrew will lead Fifth Eye to become the industry source that brings intelligence to data to inform better clinical decisions."

BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

Retrieved on: 
Monday, August 1, 2022
Patient, University, Heart failure, GLOBE, Breakthrough, Learning, U.S. Securities and Exchange Commission, Forward-looking statement, Investigator, Probability, CMS, University of Ottawa, Safety, Bone marrow, Cell, Principal, Clinical trial, Cell therapy, Review, FDA, University of Ottawa Heart Institute, Company, BCDA, Heart, Nasdaq, Security (finance), Therapy, NK1R, Pharmaceutical industry

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP Cell Therapy Heart Failure Trial.

Key Points: 
  • SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP Cell Therapy Heart Failure Trial.
  • The Ottawa Heart Institute is the first of four planned world-class Canadian clinical sites able to enroll patients in the CardiAMP Cell Therapy Heart Failure Trial, said Dr. Peter Altman, BioCardia CEO.
  • Patients interested in learning about the CardiAMP Cell Therapy Heart Failure Trial may visit www.cardiamp.com orclinicaltrials.gov, referencing trial NCT02438306 for more information.
  • The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes.

As Canada Tackles its 7th COVID-19 Wave, 15 New Studies will Examine Solutions to Omicron and Other Variants

Retrieved on: 
Wednesday, July 27, 2022
Pillar, Laboratory, Severe acute respiratory syndrome coronavirus 2, Investment, Coronavirus, University, GLOBE, Omicron, Foundation, Industry, Public, Network, Public Health Agency, Research, Canadian Institutes of Health Research, Solution, Risk, Saliva, Government, COVID-19, Public health, Computational biology, Disease, Vaccination, Mouth, Public Health Agency of Canada, Infection, University of Ottawa Heart Institute, Animal, Virology, Intrinsic immunity, Vaccine, Pharmaceutical industry

In Canada, its estimated that over 80% of current infections are due to the BA.5 Omicron subvariant1, new to Canada this spring.

Key Points: 
  • In Canada, its estimated that over 80% of current infections are due to the BA.5 Omicron subvariant1, new to Canada this spring.
  • New variants will continue to affect the global population until more solutions are found to limit transmissions.
  • As this country tackles its 7th wave, the Coronavirus Variants Rapid Response Network (CoVaRR-Net) is investing another $6.9 million to support 15 new research projects focused on better understanding Omicron subvariants and future variants and finding solutions to curb them.
  • In order to reduce the viruss spread, we must continue studying different aspects of variants to discover their vulnerabilities.

The Canadian Dermatology Association Appoints Dr. Jennifer Beecker as CDA President

Retrieved on: 
Monday, June 27, 2022
Health, Assistant, Science, Patient, American Board of Dermatology, LinkedIn, GLOBE, American, University of Ottawa Heart Institute, CDA, National, Division, Family medicine, Association, Nail, Awareness, Hair, Certification, University, Physician, Skin, Medicine, Instagram, Board, Royal college, Leadership, Twitter, Research, American Board of Commissioners for Foreign Missions, The Ottawa Hospital, Emergency medicine, Melanoma, Facebook, Dermatology

OTTAWA, June 27, 2022 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Jennifer Beecker to the position of CDA President, effective June 26, 2022.

Key Points: 
  • OTTAWA, June 27, 2022 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is pleased to announce the appointment of Dr. Jennifer Beecker to the position of CDA President, effective June 26, 2022.
  • The range of conditions in which Dr. Beecker holds expertise includes medical dermatology, skin cancer, as well as cosmetic dermatology.
  • As President, Dr. Beecker plans to focus on the strategic future of the Canadian Dermatology Association during her appointment.
  • The CDA welcomes Dr. Beecker as President, Canadian Dermatology Association for a one-year term, effective June 26, 2022.

Government of Canada makes major investment to help create world-firsts in knowledge with the Discovery Research programs

Retrieved on: 
Thursday, June 23, 2022
Statistics, Climate change, Wind, Freedom, Center, Treasury Board of Canada Secretariat, COVID-19, The Honourable, University, Physics, Environment, University of Ottawa Heart Institute, Technology, Secondary research, Biology, Artificial intelligence, Chemistry, Fishery, Institute, Knowledge, Time, Efficiency, Molecular medicine, Student, Research, Engineering, History of subatomic physics, UBC Institute for the Oceans and Fisheries, Treasury Board of Canada, Nisga'a, University of New Brunswick, Mangelia nisga, UBC, Plastic, Natural science, Sherbrooke, NSERC, Mathematics, Goal, Pharmaceutical industry, Civil engineering, Management, Discovery, Industry, Science

These include research programs focused on climate change, chemistry, biology, mathematics and statistics, computer science and artificial intelligence, and engineering.

Key Points: 
  • These include research programs focused on climate change, chemistry, biology, mathematics and statistics, computer science and artificial intelligence, and engineering.
  • Researchers are also receiving $73.8 million in one-time, one-year extensions with funds to their existing Discovery Research grants.
  • "At NSERC, we dedicate significant resources to our Discovery Research programs precisely because we cannot predict where successes will occur.
  • $73.8 million in one-time, one-year extensions with funds to existing Discovery Research grants held by more than 1,907 researchers across Canada.

The Canadian Vaping Association: THR should play a role in Canada’s Tobacco Endgame strategy

Retrieved on: 
Monday, June 6, 2022
Nicotine, University of Ottawa Heart Institute, Smoke, Ethics, Tobacco and Vaping Products Act, Policy, Smokeless tobacco, Smoker, Smoking, Center, CVA, University, Non-Smokers' Rights Association, GLOBE, THR, Risk, Health, Herbal cigarette, Adoption, Union, Tobacco, Prevalence, TVPA, Act, Death

However, it now seems unlikely that Canada will achieve this, with some calling the plan incremental, erratic and reactive tobacco control .

Key Points: 
  • However, it now seems unlikely that Canada will achieve this, with some calling the plan incremental, erratic and reactive tobacco control .
  • It is clear that traditional tobacco control measures, resulting in modest declines, will not be enough to reach this target.
  • Tobacco harm reduction (THR) products have shown considerable results in reducing smoking prevalence.
  • The 2018 amendments sought to regulate vaping products in a way that underscored that these products were harmful for youth and nonusers of tobacco products.

Theratechnologies Announces New Head of Investor Relations

Retrieved on: 
Tuesday, May 31, 2022
Company, EDGAR, Macdonald, Medication, SEDAR, NASDAQ, Public expenditure, Health, Judgement, University of Ottawa Heart Institute, Marketing, TSX, FDA, Awareness, Forward-looking statement, Human, University, Sale, HIV, Growth, Cancer, NYSE, GLOBE, Pharmaceutical industry, Economics

MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as Senior Director, Investor Relations.

Key Points: 
  • MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as Senior Director, Investor Relations.
  • "We are pleased to welcome Elif to lead our dedicated in-house investor relations efforts, said Paul Lvesque, President and Chief Executive Officer, Theratechnologies.
  • Ms. McDonald brings a wealth of experience earned over 20 years in capital markets, investor relations, financial communications, and corporate governance.
  • Further information about Theratechnologies is available on the Company's website at www.theratech.com , on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .

INFOBAE.COM: Houston doctors and researchers that are making the biggest international impact according to the KOLs list - Most of them are women

Retrieved on: 
Wednesday, May 11, 2022
Division, Department, KOL, Woman, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, MD Anderson Cancer Center, Physician, Harris Health System, University of Ottawa Heart Institute, COVID, Baylor College of Medicine, University of Texas at Austin, Internet, Cardiology, Houston Methodist Hospital, Haematopoietic system, Patient, Lists of people executed in the United States, Technology, Dentistry, Endocrinology

SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.

Key Points: 
  • SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.
  • The most researched areas in Houston after COVID are Oncology, Cardiology, and Endocrinology.
  • According to the KOLs list, the leading institutions are The University Of Texas MD Anderson, Houston Methodist, Harris Health System, Heart Institute, and Baylor College Of Medicine.
  • In healthcare, KOLs play an essential role in shaping the discourse around key issues and helping to drive change within the health system.